Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 26, 2026Blood

BCMA-directed CAR-T cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJinhui ShuMXMei‐Yan XuPLPeiru Li

Discussion

Loading...

Member takes

Overview

Clinical evaluation shows rapid platelet recovery and long-lasting remission in refractory primary immune thrombocytopenia, suggesting potential for larger studies.

Key Points

  • To evaluate the effectiveness and safety of BCMA-directed CAR-T cell therapy in patients with refractory primary immune thrombocytopenia.
  • Evaluated four patients with refractory primary immune thrombocytopenia.
  • Assessed safety and effectiveness of BCMA CAR-T cell therapy.
  • Measured platelet recovery and duration of remission.
  • All patients achieved rapid platelet recovery after treatment.
  • Durable drug-free complete remission was observed lasting up to 15 months.
  • The therapy demonstrated manageable safety profiles.

Cite This Study

Shu et al. (2026) studied this question.

synapsesocial.com/papers/6a65a91fd3aea3239cd79110https://doi.org/10.1182/blood.2026035047
View Full Paper
Ask AI
Bookmark
Share